Overview
flowchart TD
experiments_scoring_methodolog["Experiment Scoring Methodology"]
experiments_scoring_methodolog["page"]
experiments_scoring_methodolog -->|"related to"| experiments_scoring_methodolog
style experiments_scoring_methodolog fill:#81c784,stroke:#333,color:#000
experiments_scoring_methodolog["defines"]
experiments_scoring_methodolog -->|"related to"| experiments_scoring_methodolog
style experiments_scoring_methodolog fill:#81c784,stroke:#333,color:#000
experiments_scoring_methodolog["dimension"]
experiments_scoring_methodolog -->|"related to"| experiments_scoring_methodolog
style experiments_scoring_methodolog fill:#81c784,stroke:#333,color:#000
experiments_scoring_methodolog["rubric"]
experiments_scoring_methodolog -->|"related to"| experiments_scoring_methodolog
style experiments_scoring_methodolog fill:#81c784,stroke:#333,color:#000
style experiments_scoring_methodolog fill:#4fc3f7,stroke:#333,color:#000
This page defines the 10-dimension scoring rubric used to evaluate and rank proposed experiments in NeuroWiki's experiments section. Each dimension is scored on a 0-10 scale, with weighted calculations to produce a composite score (max 120 points).
Scoring Dimensions
...Overview
Mermaid diagram (expand to render)
This page defines the 10-dimension scoring rubric used to evaluate and rank proposed experiments in NeuroWiki's experiments section. Each dimension is scored on a 0-10 scale, with weighted calculations to produce a composite score (max 120 points).
Scoring Dimensions
| Dimension | Abbr | Weight | Description |
|-----------|------|--------|-------------|
| Scientific Value | SV | 2x | Potential to advance mechanistic understanding of disease processes |
| Feasibility | F | 1.5x | Practical likelihood of successful execution with current technology |
| Novelty | N | 1.5x | Degree to which the experiment addresses unexplored questions |
| Disease Impact | DI | 2x | Potential to directly benefit patients with AD, PD, or related diseases |
| Reach | R | 1x | Breadth of applicability across multiple diseases or patient populations |
| Cost Efficiency | CE | 1x | Scientific output relative to resource investment |
| Time Efficiency | TE | 1x | Timeline to meaningful results |
| Evidence Base | EB | 1x | Pre-existing data supporting the experimental approach |
| Addresses Uncertainty | AU | 1.5x | Potential to resolve key scientific unknowns |
| Translation Potential | TP | 2x | Likelihood of leading to clinical applications |
Scoring Calculation
Total Score = Σ(dimension_score × weight)
Maximum possible weighted score = 10 × 12 = 120 points
Score Interpretation
- 100-120: Exceptional priority — immediate funding recommended
- 80-99: High priority — strong candidate for rapid implementation
- 60-79: Moderate priority — valuable but may need additional validation
- 40-59: Lower priority — consider as supplementary research
- <40: Limited value — reconsider approach or scope
Detailed Rubrics
Scientific Value (SV) — Weight: 2x
| Score | Description |
|-------|-------------|
| 0-2 | No meaningful contribution to disease understanding |
| 3-4 | Confirms existing knowledge without new insights |
| 5-6 | Provides incremental advance in mechanistic understanding |
| 7-8 | Reveals novel mechanism or pathway relevant to neurodegeneration |
| 9-10 | Paradigm-shifting insight that fundamentally changes disease model |
Feasibility (F) — Weight: 1.5x
| Score | Description |
|-------|-------------|
| 0-2 | Requires technology not yet developed; >10 years to implement |
| 3-4 | Significant technical barriers; 5-10 years to overcome |
| 5-6 | Some technical challenges; 2-5 years to resolve |
| 7-8 | Mostly achievable with current methods; 1-2 years |
| 9-10 | Straightforward execution with existing techniques; <1 year |
Novelty (N) — Weight: 1.5x
| Score | Description |
|-------|-------------|
| 0-2 | Completely explored question; no new information expected |
| 3-4 | Minor variation on established approaches |
| 5-6 | Addresses underexplored angle of known mechanism |
| 7-8 | Novel experimental approach to open question |
| 9-10 | First-in-kind experiment; completely unexplored hypothesis |
Disease Impact (DI) — Weight: 2x
| Score | Description |
|-------|-------------|
| 0-2 | No direct relevance to human disease |
| 3-4 | Indirect relevance; basic science only |
| 5-6 | Relevant to disease mechanisms; potential therapeutic implications |
| 7-8 | Clear path to disease modification or treatment |
| 9-10 | Direct clinical translation; could change standard of care |
Reach (R) — Weight: 1x
| Score | Description |
|-------|-------------|
| 0-2 | Single rare subtype only |
| 3-4 | Single disease only |
| 5-6 | Relevant to one major neurodegenerative disease |
| 7-8 | Applicable to multiple neurodegenerative diseases |
| 9-10 | Broad applicability across neurodegeneration, aging, and beyond |
Cost Efficiency (CE) — Weight: 1x
| Score | Description |
|-------|-------------|
| 0-2 | >0M required for minimal information gain |
| 3-4 | -10M; information value questionable |
| 5-6 | -5M; reasonable return on investment |
| 7-8 | 00K-1M; high information value |
| 9-10 | <00K; exceptional resource efficiency |
Time Efficiency (TE) — Weight: 1x
| Score | Description |
|-------|-------------|
| 0-2 | >10 years to meaningful results |
| 3-4 | 5-10 years; long timeline |
| 5-6 | 2-5 years; reasonable |
| 7-8 | 1-2 years; rapid |
| 9-10 | <1 year; immediate actionable results |
Evidence Base (EB) — Weight: 1x
| Score | Description |
|-------|-------------|
| 0-2 | No pre-existing support; purely speculative |
| 3-4 | Weak preliminary data; high risk |
| 5-6 | Moderate preliminary evidence; some uncertainty |
| 7-8 | Strong supporting data; reasonable confidence |
| 9-10 | Comprehensive evidence base; high certainty of success |
Addresses Uncertainty (AU) — Weight: 1.5x
| Score | Description |
|-------|-------------|
| 0-2 | Does not address any key unknowns |
| 3-4 | Minor contribution to resolving uncertainty |
| 5-6 | Addresses one significant knowledge gap |
| 7-8 | Resolves multiple key questions |
| 9-10 | Could resolve fundamental controversy in field |
Translation Potential (TP) — Weight: 2x
| Score | Description |
|-------|-------------|
| 0-2 | No path to clinical application envisioned |
| 3-4 | Very long path; significant hurdles |
| 5-6 | Clear preclinical-to-clinical pathway |
| 7-8 | Near-term clinical trial potential |
| 9-10 | Immediate clinical implementation possible |
Using This Rubric
When proposing a new experiment, include a scoring table in your page:
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Scientific Value | X | [Brief explanation] |
| Feasibility | X | [Brief explanation] |
| Novelty | X | [Brief explanation] |
| Disease Impact | X | [Brief explanation] |
| Reach | X | [Brief explanation] |
| Cost Efficiency | X | [Brief explanation] |
| Time Efficiency | X | [Brief explanation] |
| Evidence Base | X | [Brief explanation] |
| Addresses Uncertainty | X | [Brief explanation] |
| Translation Potential | X | [Brief explanation] |
| Total | XX/120 | Weighted sum |
Related Pages
- [Experiment Index](/experiments/experiment-index) — View all ranked experiments](/experiments)
- [Ideas Overview](/ideas/overview) — Therapeutic idea rankings](/ideas/overview)
- [Novel Therapy Index](/ideas/novel-therapy-index) — Ranked therapy concepts
See Also
- [NeuroWiki Home](/home)
- Index Pages
References
NeuroWiki Contributors, NeuroWiki: A Mechanistic Wiki for Neurodegenerative Diseases (2026)